Altria Group Inc. is set to report its first-quarter earnings on April 30, with investors closely watching for signs of profitability amid shrinking U.S. cigarette consumption. Shares closed at $66.88 on Friday, down 0.4%, placing the company's market capitalization near $114.9 billion. The results arrive just weeks before a major leadership transition, as CEO Billy Gifford prepares to retire on May 14.
Gifford will be succeeded by Sal Mancuso, currently Altria's chief financial officer and a veteran of the company. Board chair Kathryn McQuade praised Mancuso's deep industry knowledge and understanding of the challenges facing the tobacco giant. The earnings call, scheduled for 9 a.m. Eastern on April 30, will be the last for Gifford, who will field questions alongside Mancuso.
Wall Street's expectations are modest but not negligible. Analysts surveyed by MarketBeat project first-quarter earnings of $1.25 per share on revenue of approximately $4.58 billion. The company's quarterly dividend of $1.06 per share is payable on the same day to shareholders of record as of March 25.
Altria's full-year outlook remains a focal point. In January, management guided for adjusted diluted EPS of $5.56 to $5.72 for 2026, representing growth of 2.5% to 5.5% from the $5.42 baseline in 2025. Much of that anticipated improvement is expected in the second half of the year, driven by favorable trends in cigarette import and export dynamics. Gifford highlighted continued momentum and significant cash returns to shareholders as key themes for the year ahead.
A notable tailwind could come from the so-called "double duty drawback," a U.S. regulatory mechanism that allows companies to recover federal excise taxes on cigarettes sold domestically when equivalent products are shipped abroad. Mancuso told Reuters in January that it would be "foolish" not to leverage this provision to remain competitive.
Legacy cigarette sales continue to bear the brunt of shifting consumer habits. In 2025, smokeable-products revenue fell 1.6% to $17.44 billion, net of excise taxes, as domestic cigarette shipment volume dropped 10%. Marlboro's retail share slipped to 40.5% from 41.7% a year earlier, with discount brands gaining ground amid consumer income pressures.
Altria is accelerating its push into smoke-free alternatives, particularly nicotine pouches. In March, the company announced that its Helix Innovations unit began shipping on! PLUS nicotine pouches to wholesalers, with a national retail rollout to follow. Nick MacPhee, managing director of Helix, called the launch a meaningful step forward for Altria's smoke-free ambitions.
Regulatory support has been cautious. The U.S. Food and Drug Administration has authorized six on! PLUS pouch varieties for sale, grouping them with Swedish Match USA's Zyn products. However, the agency stressed that authorization does not imply safety or FDA approval. Meanwhile, FDA reviews for some nicotine pouch brands have stalled due to concerns over youth appeal, affecting competitors like Philip Morris International (Zyn) and British American Tobacco (Velo). Jefferies analyst Andrei Andon-Ionita noted that the degree of exposure to pouches has become central to valuations for both PMI and BAT.
Altria faces the risk of not pivoting quickly enough. The company recorded $2.13 billion in non-cash impairment charges in 2025, primarily tied to its e-vapor division. Its annual report cited illicit flavored disposable e-vapor products as a drag on that segment. If cigarette volume declines accelerate or if on! PLUS fails to meaningfully erode Zyn and Velo's market share, share buybacks and tax benefits may not suffice to alter Altria's growth narrative.
